Objectives: To demonstrate and convince the audience why fat grafting should be performed in most patients who present with facial volume loss at the time of their facial rejuvenation procedure.
To discuss the major features of facial aging and why they should be addressed anatomically with multiple modalities, including biologic restoration of tissue losses
Introduction: Facial aging is associated changes in the skin surface, the deeper tissue layers and the bone. When a patient presents for facial rejuvenation, our preference is to evaluate the degree of photo-damage, the degree of volume loss and the degree of laxity and to make recommendations based on a continuum of care, ranging from prevention to non-surgical and minimally invasive approaches to a full range of surgical treatments.
Materials / method: Patients are evaluated for degree of photo-damage, volume loss and laxity. Volume loss is not a generalize finding, but is composed of losses in specific tissues including thinning of the epithelium and dermis, loss of superficial and deep compartment fat and losses of bone. From facial topography, these specific losses in each of the tissues comprising the face are evaluated and a treatment plan is composed.
Results: Patients undergoing facial rejuvenation almost always presented with volume loss. In the majority of patients, volume loss was treated with 3 types of fat grafts, a more structural graft called millifat (2mm parcel size), a microfat graft (1mm parcel size) and nanofat (500 micron parcel size). Fat was injected prior to the facelift and following grafting, the facelift was performed, generally using a high SMAS approach.
Conclusion: Each of the major features of facial aging should be simultaneously addressed and following treatment should be maintained in a serial fashion. Facial volume losses are not corrected by skin and SMAS operations alone and the vast majority of surgical candidates benefit from fat grafting that is performed as a procedure that anatomically replaces decayed tissues.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
是
请注明名称(个人,公司,学会等等): Tulip, Millenium Medical, Lipocube
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
是
请注明日期: Patent pending
和审阅情况: ITR2, Lipocube
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。